Moderna Inc. said on Tuesday it had begun a late-stage study of its vaccine for Respiratory Syncytial Virus (RSV) based on the same technology used to develop its COVID-19 shots.
The only approved product using messenger RNA (mRNA)is COVID-19 vaccine, but Moderna and rival Pfizer are rushing to tap the potential of the technology to target diseases such as shingles and cancer.
